According to VentureBeat, LabGenius Therapeutics will present scientific data at the ESMO Immuno-Oncology Congress 2025 happening December 10-12, 2025 in London. The company’s lead asset is a bispecific T-cell engager that achieved over 90% tumor growth inhibition in preclinical studies while maintaining good tolerability. LabGenius used their AI-driven EVA platform to discover and optimize this treatment, focusing on improved selectivity between healthy and cancerous cells. The presentation will mark the public debut of these promising preclinical results for their solid tumor treatment candidate.
How AI is changing drug discovery
Here’s what makes LabGenius interesting – they’re not just another AI drug discovery company. Their EVA platform combines artificial intelligence with robotic automation and synthetic biology in what they call a “high-throughput experimentation” approach. Basically, they’re using robots to test thousands of antibody variants while AI learns from the results and suggests new candidates. It’s like having a super-efficient lab assistant that never sleeps and gets smarter with every experiment.
The real challenge in cancer treatments has always been selectivity. Traditional therapies often attack healthy cells along with cancerous ones, causing those brutal side effects we all hear about. LabGenius claims their approach harnesses “avidity-driven selectivity” – meaning their treatment can distinguish between cells based on differential tumor-associated antigen expression. In plain English? It’s better at telling the difference between friends and enemies.
Why this matters now
We’re seeing a flood of AI drug discovery companies, but most are still in the early stages. What sets LabGenius apart is they have actual preclinical data showing >90% tumor growth inhibition. That’s not just theoretical – that’s real results in animal models. And they’re presenting at ESMO, which is one of the most respected oncology conferences globally. This isn’t some obscure academic meeting – it’s the big leagues.
Their hybrid business model is also worth noting. They’re pursuing their own pipeline while partnering with other biotech and pharma companies. Smart move. It gives them multiple shots on goal and helps fund their research without relying solely on investor money. You can learn more about their approach on their website or follow their updates on LinkedIn.
The bigger picture
So what does this mean for cancer treatment? If LabGenius can successfully translate these preclinical results to human trials, we could be looking at a new generation of smarter cancer therapies. Treatments that are both effective and easier on patients. But let’s be real – the graveyard of drug development is filled with promising preclinical data that never panned out in humans.
The ESMO Immuno-Oncology Congress 2025 will be the real test. That’s where experts will scrutinize their data and methodology. Still, over 90% tumor growth inhibition is nothing to sneeze at. We’ll be watching closely to see if this AI-discovered treatment can live up to the hype.
